In many obese people this regulatory mechanism does not appear to work efficiently and leads to the consumption of excess calories which the body stores as fat. This news release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the uncertainties relating to the development of new medicines and the regulatory process. It is estimated that upwards of 250 million people suffer from obesity world-wide.
Obesity develops from a chronic excess of energy intake over energy expenditure.
It is a recognised major burden to society in terms of health and socio-economic costs, with increased morbidity and mortality associated with obesity in a number of diseases. For example, epidemiological data show that obesity increases the risk of developing Type 2 diabetes, coronary heart disease, hypertension, osteoarthritis and cancer. The global obesity 'burden of illness' is therefore substantial. Vernalis Group plc Vernalis is an emerging biopharmaceutical company, with extensive expertise in the field of neuroscience and CNS medicine. The Vernalis research and development team is working on a number of disease areas including migraine, sexual dysfunction, obesity, Parkinson's disease, neuropathic pain and neuroprotection.